





Ms. Maria A. Figuerola Santos DG Health and Consumers European Commission Office 10/130 B-1049 Brussels Belgium

17 December 2012

Re: Hospital Exemption ATMPs

Dear Ms. Figuerola Santos,

The Alliance for Advanced Therapies (AAT), EuropaBio and European Biopharmaceutical Enterprises (EBE) are pleased with the European Commission's continued focus on the development of advanced therapies in Europe.

Our Associations are committed to improving the advanced therapies climate in Europe in order to bring safe and innovative treatments to patients as early as possible.

We have contacted you earlier this year about a number of possible improvements to the European advanced therapies climate, including a proper and harmonized implementation of the Hospital Exemption in the Member States.

We would appreciate the opportunity to discuss with you the improvements mentioned above and our plans for coordinated follow-up activities. We therefore kindly request a meeting with you.

Please do not hesitate to contact us with any questions that you might have.

We look forward to your response.

Kind regards,

Alliance for Advanced Therapies

Rob T.A. Janssen Secretary-General

EuropaBio

Miriam Gargesi Healthcare Director

European Biopharmaceutical Enterprises

Titta Rosvall-Puplett Executive Director







Alliance for Advanced Therapies Palissanderhout 2 2719 KW Zoetermeer The Netherlands

Tel.: +31 79 362 29 50 Fax.: +31 79 360 03 06 Mob.: +31 6 54 70 88 65

E-mail: <u>info@allianceat.org</u> Web: <u>www.allianceat.org</u>

EuropaBio

Avenue de l'Armée 6 1040 Brussels Belgium

General phone number: +32 2 739 11 74 Fax number: +32 2 735 49 60

E-mail: d.cassidy@europabio.org

European Biopharmaceutical Enterprises

Rue du Trône 108 Leopold Plaza Building B-1050 Brussels Belgium

T: +32 2 626 25 55 F: +32 2 626 25 66

E-mail: <u>info@ebe-biopharma.org</u> Web: <u>www.ebe-biopharma.org</u>